You may wonder how long GLP-1 takes to work after your first dose of Wegovy® or Zepbound®. The waiting can feel hard when you are hopeful and a little nervous at the same time.
Maybe the scale has not moved yet, and you are asking if something is wrong. That worry is very common in the early weeks.
Here is the calm truth. These medicines work slowly and steadily, not overnight. This page shows what the trials found, so you know what to expect.
Key takeaways
- GLP-1 medicines like Wegovy® and Zepbound® work gradually, not in a single week.
- Appetite often eases before the scale moves much, so early wins can be quiet.
- In STEP 1, Wegovy® 2.4 mg reached about 14.9% weight loss over 68 weeks.
- In SURMOUNT-1, Zepbound® 15 mg reached about 20.9% weight loss over 72 weeks.
- Results vary by person, and both brands carry a boxed warning for thyroid C-cell tumors.
What this guide answers
- How long does a GLP-1 like Wegovy® or Zepbound® take to work?
- Do appetite changes show up before the scale moves?
- What did the STEP 1 and SURMOUNT-1 trials actually show over time?
- Why do my results look different from someone else's?
- When should I speak with my prescriber about timing or side effects?
How long GLP-1 takes to work: Wegovy® and Zepbound® timelines
Weight loss on these medicines comes off slowly across many months. It is a gradual climb, not a sudden drop.
Wegovy® (brand of semaglutide) and Zepbound® (brand of tirzepatide) were both studied over more than a year. The full results took the whole trial to appear.
In the STEP 1 trial of 1,961 adults, Wegovy® 2.4 mg reached about 14.9% weight loss at 68 weeks. Weight fell bit by bit across those weeks.
In the SURMOUNT-1 trial of 2,539 adults, Zepbound® 15 mg reached about 20.9% weight loss at 72 weeks. That loss also built up steadily over time.
So the honest answer is patience. The medicines start their work early, yet the visible weight change grows month after month.
Many people notice changes in appetite well before the scale shifts. That is a normal and encouraging part of the process.
When appetite changes may show up first
GLP-1 medicines act on signals that affect hunger and fullness. Because of this, appetite often changes before your weight does.
You may feel full sooner at meals or think about food less often. Some people notice this in the first weeks, though timing varies.
These quiet changes can be easy to miss. You might eat a bit less without planning to, and only notice later.
The scale can lag behind these early shifts. Your habits may change first, and the number follows over the coming weeks.
This gap is not a sign that the medicine is failing. It is a common pattern while your body adjusts to a new routine.
Watching for appetite cues, not just the scale, can help you stay hopeful. Small changes early can point to bigger changes ahead.
Appetite often eases before the scale moves, so early progress on Wegovy® or Zepbound® can be quiet at first.
Wegovy® (brand of semaglutide) results in the STEP 1 trial
Wegovy® is a brand of semaglutide approved for chronic weight management. The STEP 1 trial studied how much weight adults lost over time.
STEP 1 followed 1,961 adults for 68 weeks. Those taking Wegovy® 2.4 mg lost about 14.9% of body weight, versus about 2.4% with placebo.
The weight came off progressively across the full trial. It did not all happen at once, and it flattened toward a plateau near the end.
This shape matters for your own timeline. Early weeks may show smaller changes, with more of the result arriving later.
The dose also builds up slowly, which shapes the pace. You do not start at the full amount on day one.
Knowing this can ease the pressure of the first month. The trial suggests the biggest changes take many months to appear.
Zepbound® (brand of tirzepatide) results in the SURMOUNT-1 trial
Zepbound® is a brand of tirzepatide approved for chronic weight management. The SURMOUNT-1 trial measured weight loss across more than a year.
SURMOUNT-1 followed 2,539 adults for 72 weeks. Those taking Zepbound® 15 mg lost about 20.9% of body weight, versus about 3.1% with placebo.
As with Wegovy®, the loss in SURMOUNT-1 accrued steadily. It grew over the weeks rather than arriving in a single burst.
There is no verified early-week landmark to quote for Zepbound®. The honest picture is a gradual, month-by-month change.
So both brands share the same basic pattern. Steady loss over many months, with the full result taking the whole trial.
These results apply only to the FDA-approved branded product and do not transfer to compounded preparations. Compounded semaglutide and tirzepatide are not FDA-approved and are not a generic of Wegovy® or Zepbound®. They are not evaluated by the FDA for safety, effectiveness, or quality.
| Brand | FDA-approved use | Named trial and result | How the change appeared |
|---|---|---|---|
| Wegovy® (brand of semaglutide) | Chronic weight management | STEP 1, N=1,961: about 14.9% weight loss vs 2.4% placebo at 68 weeks | Progressive across the trial, plateau near the end |
| Zepbound® (brand of tirzepatide) | Chronic weight management | SURMOUNT-1, N=2,539: about 20.9% at 15 mg vs 3.1% placebo at 72 weeks | Steady, month by month over 72 weeks |
Both branded medicines showed gradual weight loss across trials lasting more than a year.
Why the dose schedule affects timing
You do not start Wegovy® or Zepbound® at the full dose. Both begin low and step up slowly, which shapes how fast you see change.
This slow build is called titration. It gives your body time to adjust and helps ease stomach side effects.
Here is the general path for Wegovy® (brand of semaglutide), stepping up every 4 weeks:
1. Wegovy®: weeks 1 to 4 start at 0.25 mg once weekly, an entry dose, not a treatment dose.
2. Wegovy®: weeks 5 to 8 move to 0.5 mg once weekly.
3. Wegovy®: weeks 9 to 12 move to 1 mg once weekly.
4. Wegovy®: weeks 13 to 16 move to 1.7 mg once weekly.
5. Wegovy®: week 17 and on reach the 2.4 mg maintenance dose, or stay at 1.7 mg.
Zepbound® (brand of tirzepatide) follows a similar idea. You start at 2.5 mg once weekly for 4 weeks, then move to 5 mg.
After that, Zepbound® can rise in 2.5 mg steps, with at least 4 weeks between changes. Maintenance doses are 5, 10, or 15 mg.
Because the dose climbs over months, the strongest effect often comes later. That is one reason the early weeks can feel slow.
Both Wegovy® and Zepbound® start low and step up every few weeks, so the strongest effect often arrives later.
Why results vary from person to person
Trial averages describe a group, not any single person. Your own pace can look different, and that is normal.
Your starting weight, your dose, and your daily habits all play a part. Food, movement, sleep, and stress can each shape your results.
Two people on the same brand may lose weight at different speeds. Bodies respond in their own way to the same medicine.
Where you are in the titration schedule matters too. Someone at a maintenance dose may see faster change than someone just starting.
No brand can promise a set number or a set timeline. Be careful of anyone who guarantees a fast, exact result.
Comparing yourself to others can steal your hope. Your steady progress counts, even when it looks different from a friend's.
How long the medicines keep working
These medicines work while you keep taking them. Obesity is a long-term condition, so treatment is often long-term too.
Trials looked at what happens when people stop. The pattern shows why staying on a plan matters.
In a STEP 1 extension, people who stopped Wegovy® at week 68 regained about two-thirds of lost weight by week 120. That was one year off the medicine.
In the SURMOUNT-4 trial of 670 adults, those switched to placebo regained about 14.0% of body weight. Those who kept taking Zepbound® lost a further 5.5%.
So weight regain after stopping is expected, and it is a class pattern. It is not a personal failure if the weight returns.
The label does not define a taper or a lower upkeep dose. Any change to your plan is a conversation for your prescriber.
Weight regain after stopping is an expected class pattern, so any plan to pause or stop is a conversation for your prescriber.
When to speak with your prescriber
Your prescriber is your best guide for timing and dose questions. Reach out if progress feels stalled or side effects feel hard.
Acute pancreatitis has been seen in people who use GLP-1 medicines. Warning signs include severe belly pain that may spread to the back, with or without vomiting.
If you notice these signs, get medical care right away, and your prescriber may stop the medicine. Fast action matters here.
Talk with your prescriber before changing your dose or stopping. They can help you weigh the timing shown in the trials.
If you are considering a GLP-1 for a use that is not FDA-approved, raise that too. Off-label choices deserve a careful, honest discussion.
You do not have to sort this out alone. A trusted care team can help you set fair expectations and a safe pace.
Frequently asked questions
How soon will I lose weight on Wegovy® or Zepbound®?
Weight loss is gradual, not instant. In STEP 1, Wegovy® 2.4 mg reached about 14.9% over 68 weeks, and in SURMOUNT-1, Zepbound® 15 mg reached about 20.9% over 72 weeks. Both trials showed loss building month by month. Many people notice appetite changes before the scale moves, so early progress can be quiet at first.
Why is the scale not moving in my first weeks?
Early weeks often bring smaller changes. You start at a low dose that steps up every few weeks, so the strongest effect tends to come later. Your appetite may ease before your weight shifts, which is a common pattern. If you feel worried, your prescriber can review your progress and answer questions about your timeline.
Do appetite changes come before weight changes?
Often, yes. GLP-1 medicines act on signals tied to hunger and fullness, so many people feel full sooner or think about food less. These quiet changes can show up before the scale moves much. The number on the scale may follow over the coming weeks. Watching appetite cues, not just weight, can help you stay encouraged.
Is Zepbound® faster than Wegovy®?
Both work gradually over more than a year. In SURMOUNT-1, Zepbound® 15 mg reached about 20.9% over 72 weeks, while in STEP 1, Wegovy® 2.4 mg reached about 14.9% over 68 weeks. There is no verified early-week figure to compare speed. Results vary by person, so your pace may differ from any trial average.
What happens if I stop taking the medicine?
Weight regain after stopping is expected and is a class pattern. In a STEP 1 extension, people regained about two-thirds of lost weight a year after stopping Wegovy®. In SURMOUNT-4, those switched to placebo regained about 14.0%. Obesity is a long-term condition, so any plan to pause or stop should be discussed with your prescriber first.
Why do my results look different from a friend's?
Trial numbers are group averages, not personal promises. Your starting weight, your dose, and your habits around food, movement, and sleep all shape your pace. Where you are in the titration schedule matters too. Two people on the same brand can lose weight at different speeds. No brand can promise a set result or timeline.
When should I call my prescriber about timing?
Reach out if progress feels stalled, if side effects feel hard, or if you are thinking about changing your dose. Get care right away for severe belly pain that may spread to the back, with or without vomiting, since this can signal pancreatitis. Your prescriber can set fair expectations and a safe pace for you.
Keep reading
Keep reading: GLP-1 for weight loss: your starting point
New to GLP-1 medicines for weight loss? Start with the basics of how they fit into a weight plan.
Read more →Important: This page is for education only and is not medical advice. Any medicines named here are available by prescription. Always talk to a licensed clinician about medicines, symptoms, or anything you are considering.
Comments